To address the metastatic and treatment-resistant challenges of triple-negative breast cancer (TNBC), a team developed red blood cell membrane-camouflaged nanoparticles (SB-IR-PLGA@RM), which encapsulate the sonosensitizer IR780 and TGF-β inhibitor SB431542 to drive TAMs and neutrophils towards an anti-tumor phenotype, reshaping the microenvironment, inhibiting cancer-associated fibroblast (CAF) activation, and blocking EMT. The gene discussed is TGFB1; the disease is neoplasm.